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Abstract Rationale: The density of tyrosine hydroxylase-
immunoreactive (TH-IR) axons in the prefrontal cortex of
schizophrenic subjects may be reduced by as much as 50% in
the deep cortical layers (Am J Psychiatry 156:1580–1589,
1999). Previously, we demonstrated that ~60% loss of TH-IR
axons in the rat medial prefrontal cortex (mPFC) decreases
local basal and stress-evoked extracellular dopamine (DA)
concentrations, suggesting that moderate loss of DA axons in
the mPFC is sufficient to alter the neurochemical activity of
the remaining DAneurons (Neuroscience 93:497–505, 1999).
Objectives: To further assess the functional consequences of
partial mPFC DA depletion, we examined the effects of 6-
hydroxydopamine lesions of the rat mPFC on behavior in a
T-maze delayed-response task. We also assessed whether
chronic administration of the norepinephrine (NE) uptake
inhibitor, desipramine (DMI), attenuates lesion-induced def-
icits in T-maze performance. Previous research indicates that
inhibition of NE transport in the mPFC results in a concom-
itant increase in extracellular DA andNE. Results: Moderate
loss of mPFC DA and NE (~50 and 10% loss, respectively)
was sufficient to impair delayed-response behavior, in part
due to an increase in perseverative responding. Chronic DMI
treatment (3 mg/kg delivered via osmotic pumps) im-
paired performance of control rats but attenuated the
deficits in delayed-response behavior in rats previously
sustaining loss of mPFC DA and NE (~75 and 35% loss,
respectively). Conclusion: These data suggest that mod-
erate loss of DA and NE in the prefrontal cortex is
sufficient to impair cognitive function, and these behav-
ioral effects are attenuated by inhibition of the NE
transporter.
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Introduction
Converging evidence supports an inverted U-shaped relation
of mesoprefrontal dopamine (DA) neuron activity and cog-
nitive performance, such that DA receptor stimulation above
or below an optimum level gives rise to cognitive deficits
(Arnsten 1997; Granon et al. 2000; Zahrt et al. 1997).
Dysfunction of the mesoprefrontal DA system has long been
thought to contribute to the cognitive deficits associated with
schizophrenia (Jaskiw and Weinberger 1992; Robbins 1991).
In support of this hypothesis, local application of DA antag-
onists or DA depletion of themedial prefrontal cortex (mPFC)
in experimental animals produces cognitive deficits reminis-
cent of those seen in schizophrenic subjects (Arnsten et al.
1994; Brozoski et al. 1979; Bubser and Schmidt 1990;
Ellenbroek et al. 1996; Granon et al. 2000; Koch and Bubser
1994; Sawaguchi and Goldman-Rakic 1991; Sawaguchi and
Goldman-Rakic 1994). Immunocytochemical analyses of
postmortem tissue from schizophrenic subjects have con-
firmed that the density of prefrontal cortex nerve fibers im-
munoreactive for tyrosine hydroxylase (TH-IR) and DA
transporter protein is reduced by up to 50% (Akil et al. 1999).
A decrease in size and number of neuromelanin-containing
cell bodies has also been observed in the ventral tegmental
area of schizophrenic subjects (Bogerts et al. 1983). A mod-
erate reduction in TH-IR fibers in the rat mPFC is sufficient to
reduce basal and stress-evoked extracellular DA concentra-
tions in this brain region (Venator et al. 1999). The present
studies examined whether moderate reductions in the DA
innervation of the rat mPFC, comparable to that observed in
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schizophrenic subjects, are sufficient to induce cognitive def-
icits as assessed using a T-maze alternation task.
DA agonists attenuate lesion-induced cognitive deficits
in animals previously sustaining loss of prefrontal cortex
DA (Brozoski et al. 1979) and improve cognitive per-
formance and cognitive activation of cerebral blood flow in
the frontal cortex of schizophrenic subjects (Daniel et al.
1989; Daniel et al. 1991; Dolan et al. 1995; Fletcher et al.
1996; Geraud et al. 1987). However, DA agonists also
evoke or exacerbate hallucinations and delusions in schizo-
phrenic subjects (Angrist et al. 1985; Angrist et al. 1980; van
Kammen et al. 1982), perhaps as a result of increasing activity
at subcortical DA receptors. In contrast, norepinephrine (NE)
uptake inhibitors have been found to increase extracellularDA
in the PFC, while leaving subcortical DA systems largely
unaffected (Carboni et al. 1990; Gresch et al. 1995; Moron et
al. 2002; Yamamoto and Novotney 1998) These effects are
thought to reflect the fact that NE transporters located on
noradrenergic axons contribute to clearance of extracellular
DA in the NE-rich mPFC, but not in DA-rich/NE-poor sub-
cortical sites. The present studies examined whether chronic
administration of the NE transport inhibitor desipramine
(DMI) alleviates cognitive deficits induced by partial loss of
DA in the rat mPFC.
Experimental procedures
Animals and materials
Male Sprague–Dawley rats (Hilltop, Scottdale, Pennsylvania)
were housed singly in wire mesh cages (20×20×30 cm) in a
temperature-controlled room (22–23°C). Room lights were on
from 8:00 a.m. to 8:00 p.m. Rats were allowed at least 1 week
to acclimate to the colony room prior to any treatment. During
this time, rodent chow and water were available ad libitum.
Procedures for the treatment of rats were approved by the
Institutional Animal Care Use Committee at the University of
Pittsburgh and Western Washington University using criteria
established by the U.S. Animal Welfare Act and the National
Institutes of Health Guide for the Care and Use of Laboratory
Animals.
6-OHDA lesions of the mPFC
6-Hydroxydopamine (6-OHDA) lesions of the mPFC were
performed as previously described (King and Finlay 1995;
Venator et al. 1999). Briefly, rats weighing 220–250 g were
treated with DMI hydrochloride (25 mg base/kg, i.p.;
Sigma Chemical Co., St. Louis, MI) 30 min prior to an-
esthesia with Equithesin (3 ml/kg, i.p.). Using a stereo-
taxic instrument (David Kopf Instruments, Tujunga, CA), a
glass pipette (tip o.d.=50–100 μm) was positioned in the
mPFC at the following coordinates: AP +3.2 and ML
±0.8 mm from bregma, and DV −3.2 mm from dura with a
flat skull (Paxinos and Watson 1986). After the pipette was in
position for 5 min, 1.0 μg 6-OHDA base (prepared from 6-
OHDA hydrochloride; Sigma) in 2 μl of vehicle (0.9% so-
dium chloride containing 0.03% ascorbic acid) was infused
into each site over 5 min using pressure ejection (World Pre-
cision Instruments PV820 Pneumatic Picopump, Sarasota,
FL). The glass pipette was left in position for an additional
5min to allow for dispersal of the toxin. After recovering from
anesthesia, rats were returned to their cages in the colony room
where they remained undisturbed for 1 to 2 weeks.
T-maze delayed-response training and testing
AT-maze was constructed of clear acrylic. The main alley
was 90 cm long and 11 cm wide. The initial 30 cm of the
main alley constituted the start box and could be partitioned
from the remainder of the main alley using a moveable door.
The main alley terminated in two arms, each 50 cm long and
10 cm wide, extending at 90° angles to the right and left of
the main alley. Moveable doors were located at the start of the
main alley and 20 cm from the end of each arm. Reward
receptacles, located at the ends of each arm, were positioned
below floor level to prevent rats from seeing whether the dish
was baited. The walls of the maze were 10 cm in height, and
the entire maze was covered by a clear acrylic lid. The floor,
walls, and doors of the maze were painted black.
The protocol for the T-maze delayed-response task was
based on a previously published method (Thomas and
Gash 1988). Briefly, the task consisted of several days of
habituation, one-arm adaptation, alternation, and delayed-
response trials. During habituation trials (began 1–2 weeks
postlesion), rats were placed in the start box of the main
alley. The door of the start box was immediately opened,
allowing the rat free access to the maze and reinforcers (1/2
of a milk-chocolate chip) located in the receptacles at the
end of the arms. On habituation days 1 and 2, rats were
confined to themaze for 5 and 3min, respectively. Subsequent
exposureswere 2min each in duration. Daily habituation trials
continued until all rats were consuming the chocolate (4–
6 days). During one-arm adaptation trials, rats were placed in
the start box of the main alley, and the door was immediately
opened allowing free access to the main alley and one ran-
domly selected arm, baited with chocolate. Access to the
alternate arm was blocked by the removable door. Rats were
given six 1-arm adaptation trials per day. Daily one-arm ad-
aptation trials were continued until all rats were consuming the
chocolate on all trials (5 days). Alternation trials were com-
prised of an information run and a choice run. During the
information run, rats were placed in the start box, and the door
was immediately opened to allow free access to the main alley
and 1-arm baited with chocolate. Immediately following con-
sumption of the chocolate, rats were returned to the start box
for the initiation of the choice run. The door of the start box
was immediately opened to allow free access to the main alley
and both arms. Only the arm not previously entered on the
information run was baited. As soon as the front half of the
rat’s torso was within an arm, the door at the entry was closed,
confining the rat to the arm. Regardless of whether the choice
run resulted in reinforcement, it was followed by the next
information run. Rats performed six such alternation trials per
day until the average performance of each group reached a
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criterion of 75–80% correct responses on 2 consecutive days
(5–8 days). The procedure for delay trials was identical to
alternation trials with the exception that a 30-, 60-, or 90-s
delay was introduced between the information and test runs.
Retention intervals were similar to those used in previously
published research examining the role of mPFC in working
memory (Aultman and Moghaddam 2001; Bubser and
Schmidt 1990; Jentsch et al. 1997). During delays, rats were
housed in a cylindrical clear acrylic cage (27 cm diame-
ter×40 cm high). Six delay trials (two of each delay) were
conducted daily for 5 days. The order of delay presentations
within a day was randomized across trials. Throughout T-
maze training and testing, the floor of the maze was wiped
with unscented baby wipes between every trial.
All behavioral training/testing was performed during the
light phase of the light–dark cycle. Rats were maintained at
body weights that were 85–90% of a group of age-matched
free-feeding control rats. Following each behavioral train-
ing/testing session, rats were weighed, returned to their
cages, and given a quantity of rodent chow sufficient to
maintain the target body weight. On nontraining/testing
days, chow was placed in each cage at a random time
during the light phase of the light–dark cycle.
Chronic drug administration
Osmotic pumps (Alzet Model 2ML4; Alza Corporation,
Palo Alto, CA) were implanted immediately following the
last T-maze habituation trial. Control and lesioned rats
(n=13 and 11, respectively) were anesthetized (Equithesin,
3 ml/kg, i.p.), and pumps were implanted subcutaneously
on the lateral aspect of the torso, caudal to the left or right
forelimb. Osmotic pumps delivered 3 mg DMI base (DMI
hydrochloride; Sigma) in 60 μl of 0.9% sodium chloride
per day for the remainder of the experiment (~11 mg/kg
DMI base per day). Sustained delivery of DMI via osmotic
pumps did not result in tissue necrosis commonly seen fol-
lowing repeated subcutaneous injections. Drug-naïve control
and lesioned rats were either untreated, or osmotic pumps
were implanted to deliver 60 μl of vehicle per day. Because
the behavior of untreated and vehicle-treated rats did not
differ, data from these groups were combined for analysis of
behavior in drug-naive control and lesioned groups (n=24
and 18, respectively).
Tissue preparation and neurochemical analyses
Local application of 6-OHDA produces a rapid and per-
sistent loss of brain catecholamines (Bell et al. 1970; Boyce
and Finlay 2005). To determine lesion size in the present
study, tissue preparation was performed approximately
14 days after behavioral testing was completed, using pre-
viously published methods (King and Finlay 1997). Briefly,
rats were decapitated, the brains were removed, and the left
and right mPFC were dissected from 1.4-mm-thick coronal
sections cut at the level of the mPFC. Tissue samples were
weighed, homogenized, centrifuged, and filtered. The re-
sulting supernatant was stored at −80°C until analyzed. DA,
NE, and 3,4-dihyroxyphenylacetic acid (DOPAC) con-
centrations in the supernatant were determined using
high-pressure liquid chromatography (HPLC) with elec-
trochemical detection. The assay conditions were similar
to those used previously in our laboratory (Venator et al.
1999). Peak separation was accomplished using a reversed-
phase C18 column (ESA, Part #70-0636, Chelmsford, MA)
and mobile phase (ESA, Part #71-1332). Electrochemical
detection was performed using amperometric (Waters,
Model 460) or coulometric detection (ESA, Model 5100A).
Oxidation peaks produced by analyzing supernatant were
compared to those produced by standards of a set con-
centration. Acquisition and analysis of chromatograms
were performed using a computer (Dynamax Macinte-
grator HPLC Method Manager, Rainin Instrument Co.,
Emeryville, CA).
Statistical analyses
Tissue DA, DOPAC, and NE concentrations (nanograms
per milligram tissue wet weight) in the mPFC of control
and 6-OHDA-lesioned rats were analyzed using one-way
ANOVAs. Behavioral data were analyzed using one-way
ANOVAs, two-way repeated measures ANOVAs, or in-
dependent samples t tests. Degrees of freedom appropriate
to the Greenhouse–Geisser F test were used in evaluating
the results of repeated measures ANOVAs (Kirk 1982);
however, the unadjusted degrees of freedom are reported.
The level of significance for all ANOVAs was P≤0.05.
Following a significant overall F value, pairwise compar-
isons were performed using “layered” Bonferroni t tests
(Darlington 1990). Data analyses were performed using
SPSS for Windows (SPSS Inc., Version 10.1, Chicago, IL).
All data are presented as mean±SEM.
Results
Effects of 6-OHDA lesions of the mPFC on T-maze
performance
Local infusions of 6-OHDA decreased absolute DA and
NE concentrations in the mPFC [Table 1; t(39)=7.00 and
2.03, respectively]. Based on the percentage loss of DA in
the mPFC, the lesioned group was divided, a posteriori,
into two groups via a median split. This split resulted in
lesioned groups characterized by ~50 and 85% loss of
tissue DA concentrations relative to control [smaller and
larger lesion groups, respectively; F(2,38)=40.3; t(30)=4.6
and 7.6, respectively]. In rats sustaining larger loss of DA,
tissue NE and DOPAC content were also reduced relative
to controls [F(2,38)=3.7 and 3.4, respectively; t(30)=2.8
and 2.4, respectively]. In contrast, tissue NE and DOPAC
concentrations in rats sustaining smaller lesions were not
significantly different from control values.
Control and smaller and larger lesioned rats exhibited
similar behavior during alternation training. All groups
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achieved performance accuracies of 75–80% correct re-
sponses and made choices within ~4.0 s of being released
from the start box (Fig. 1). Performance on the final day of
alternation training was compared to that observed when 30-,
60-, and 90-s delays were imposed between information and
choice runs (Fig. 2a). Control rats and rats sustaining larger
lesions exhibited a decline in response accuracy under the 90-s
delay condition [Control: F(3,69)=4.8 and t(23)=4.5; Larger
lesion: F(3,24)=4.5 and t(8)=2.5], whereas rats sustaining
smaller lesions exhibited fewer percent correct responses
under 30-, 60-, and 90-s delay conditions [F(3,24)=9.7; t(8)=
4.0, 4.8, and 4.9, respectively]. Delay trial performance was
also assessed for lesion-induced alterations in the latency to
select an arm (latency timing began when the start box door
opened and ended when a choice arm was selected; latencies
were determined for both correct and incorrect choices) and
perseverative responding (the number of consecutive selec-
tions of the same arm divided by the number of consecutive
selections of the same arm required to achieve 100% ac-
curacy). Because latencies and perseveration scores did not
vary as a function of delay duration, data were collapsed
across this variable. Similarly, data were collapsed across the
variable of lesion size since rats sustaining smaller and larger
lesions exhibited similar choice latencies (2.7±0.4 and 2.3±
0.2 s, respectively) and perseveration scores (1.8±0.2, both
groups). Partial depletion of DA in the rat mPFC did not alter
delay trial choice latencies (Fig. 2b). However, relative to
controls, lesioned rats exhibited a 20% increase in persevera-
tive responding during delay trials [Fig. 2c; t(40)=2.1].
Effects of chronic DMI on T-maze performance in rats
previously sustaining 6-OHDA lesions of the mPFC
The effects of chronic DMI (3 mg/day) on delayed-response
behavior were assessed in control rats and rats previously
sustaining 6-OHDA lesions of the mPFC. Neurochemical and
behavioral data from the DMI-treated groups were compared
to those obtained from the drug-naïve control and lesioned rats
presented above (as noted in “Experimental procedures”,
these rats were either untreated or received vehicle infusions).
DA concentrations in the mPFC of DMI-treated lesioned rats
were reduced by ~75% relative to DMI-treated control rats
(0.02±0.01 and 0.08±0.01 ng/mg tissue, respectively; t(20)=
4.6], and NE concentrations were reduced by ~35% [0.20±
0.08 and 0.31±0.10 ng/mg tissue, respectively; t(20)=2.9].
DA and NE concentrations in the mPFC of DMI-treated
control and lesioned rats did not differ fromdrug-naïve control
and lesioned rats, respectively, indicating that prior chronic
administration of DMI did not impact the quantification of
lesion size. Based on the percentage loss of mPFC DA, the
DMI-treated lesioned group was divided, via a median split,
into a smaller and larger lesion group (~50 and 90% loss of
tissue DA). Because subsequent statistical analyses revealed
that the behavior of DMI-treated lesioned rats did not vary




Control (n=23a) 0.07±0.01 0.23±0.03 0.04±0.01
Lesion (n=18) 0.02±0.00* 0.14±0.02* 0.02±0.01
(% of controlb)
Smaller lesion (n=9) 47±3* 88±20 71±13
Larger lesion (n=9) 14±2* 44±8* 51±9*
DA dopamine, NE norepinephrine, DOPAC 3,4-dihyroxyphenyla-
cetic acid
*Significantly different from control (independent samples t tests
with layered Bonferroni correction in the case of multiple
comparisons, P≤0.025–0.05)
aSamples of one control rat were omitted from the neurochemical
analyses due to contamination. Local infusions of 6-OHDA
reduced absolute DA and NE concentrations in the mPFC
bBased on the percentage loss of tissue DA, the lesioned group was
divided, a posteriori, into two groups via a median split. Relative to
the control group, mPFC DA content was reduced in the smaller
and larger lesion group. Tissue NE and DOPAC concentrations
were also reduced in rats sustaining larger, but not smaller, loss of
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Fig. 1 Effects of 6-OHDA le-
sions of the MPFC on perfor-
mance during the last 5 days of
T-maze alternation trials (n=24
control, n=9 lesion/group). Per-
cent correct responses and
choice latency (inset) were sim-
ilar in control and lesioned rats.
Data are presented as group
mean±SEM
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significantly as a function of lesion size, behavioral data were
collapsed across this variable for analysis.
Average percent correct responses and choice latencies
over the last 5 days of alternation trials were calculated for
DMI-treated control and lesioned rats and drug-naïve control
and lesioned rats. DMI-treated control rats exhibited fewer
percent correct responses than drug-naïve control rats, naïve-
lesioned rats, and DMI-lesioned rats [Fig. 3a; F(3,61)=4.3); t
(35)=2.5, t(29)=2.1, and t(22)=2.7, respectively]. DMI-
treated control rats sometimes failed to select an arm within
90 s of initiation of a choice run (~1 trial/day). Response
failures were coded as an error in the data presented in
Fig. 3a. When trials associated with response failures were






















































































Smaller & Larger Lesion
Fig. 2 Effects of 6-OHDA lesions of the mPFC on performance
accuracy, choice latency, and perseverative errors during T-maze
delayed-response trials (n=24 control, n=9 lesion/group). a Relative
to the final day of alternation trials, rats sustaining smaller lesions
exhibited impaired performance under 30-, 60-, and 90-s delays.
Control and larger lesion rats exhibited impaired performance only
under the 90-s delay condition. bChoice latencies and c perseverative
errors were collapsed across delay and lesion size. Partial loss of
mPFC DA did not affect choice latency but increased perseverative
responding. Data are presented as group mean±SEM. +Significantly
different from corresponding within-group alternation trials (paired
samples t tests with layered Bonferroni correction, P≤0.017–0.05).














































































Fig. 3 Effects of chronic DMI (3 mg/day delivered via osmotic
pumps) on percent correct responses (a) and choice latencies (b)
during T-maze alternation trials in control rats and rats previously
sustaining ~75% loss of DA in the mPFC (n=13 DMI-control, n=11
DMI-lesion, n=24 drug-naïve control, n=18 drug-naïve lesion).
Because the behavior of DMI-treated lesioned rats did not vary
significantly as a function of lesion size, data were collapsed across
this variable. Average percent correct responses and choice latencies
were calculated for each treatment condition, collapsing across
5 days of alternation trials. DMI-control rats exhibited fewer percent
correct responses than drug-naïve control rats, naïve-lesioned rats,
and DMI-lesioned rats (n=13, 24, 18, and 11, respectively). Chronic
DMI increased choice latency in control and lesioned rats, relative to
the corresponding drug-naïve condition. Data are presented as group
mean±SEM. *Significantly different from all other treatment
conditions (independent samples t tests with layered Bonferroni
correction, P≤0.012–0.05). **Significantly different from corre-
sponding naïve-control and naïve-lesion group (independent sam-
ples t tests with layered Bonferroni correction, P≤0.012–0.05)
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control rats (73±5% correct responses) did not differ
significantly from that of the other treatment conditions.
Relative to their drug-naïve comparison groups, DMI-treated
control and lesioned rats also exhibited increased choice
latencies during alternation trials [Fig. 3b; F(3,61)=12.0;
t(32)=4.4 and t(27)=4.2, respectively].
Following alternation trials, the performance of drug-naïve
and DMI-treated control and lesioned rats was evaluated
under conditions of 30-, 60-, and 90-s delays between infor-
mation and choice runs (Fig. 4). Consistent with their per-
formance on alternation trials, DMI-treated control rats
exhibited 50–60% correct responses during delay trials. This
level of performance was significantly below that of drug-
naïve control rats and DMI-treated lesioned rats [group main
effect: F(3,51)=3.3; t(35)=2.33 and t(22)=2.55, respectively].
Relative to their respective within-group alternation trials,
drug-naïve control rats and DMI-treated lesioned rats exhib-
ited impaired performance only under the 90-s delay condition
[t(23)=4.51 and t(10)=2.43]. During delay trials, DMI-treated
control rats again sometimes failed to select an armwithin 90 s
of initiation of a choice run (~2 trials/day). Response failures
were coded as an error in the data presented in Fig. 4. When
trials associated with response failures were omitted from the
data set, performance of DMI-treated control rats did not differ
from that of DMI-treated lesioned rats (averaging 64±4% and
69±4% correct responses across all delay trials, respectively).
Discussion
Effects of 6-OHDA lesions of the mPFC on T-maze
performance
Postmortem analyses have revealed a modest decrease in
TH-IR nerve terminals in the PFC of schizophrenic sub-
jects, approaching a maximum of ~50% in the deep cortical
layers (Akil et al. 1999). The goal of the present study was
to determine whether, in rats, this structural abnormality is
sufficient to impair the functional capacity of the remaining
mesoprefrontal DA neurons. Our results indicate that ~50%
loss of tissue DA content in the rat mPFC impaired per-
formance on T-maze delayed-alternation trials. During
acquisition of the task, performance accuracy of rats sus-
taining ~50% loss of mPFC DA was similar to that of
control rats. However, when delays of 30-, 60-, and 90-s
were introduced between the information and choice runs,
lesioned rats exhibited greater performance deficits than
controls. The lesion-induced decrease in accuracy was as-
sociated with increased perseverative responding. The
present data are consistent with earlier reports indicating
that delayed-response behavior is impaired in nonhuman
primates and rats sustaining ≤50% loss of PFC DA
(Roberts et al. 1994; Stam et al. 1989). In contrast, results
of an early study suggested that ~50% loss of PFC DA has
no effect on spatial delayed-response behavior in non-
human primates (Brozoski et al. 1979). The lack of effect of
moderate lesions in the latter study may have been related
to the use of a within-subject experimental design in which
subjects were trained and tested on the delayed-response
task prior to lesioning. Moderate loss of DA terminals in
the rat mPFC has been found to impair the neurochemical
activity of this system (Venator et al. 1999). In the latter
study, absolute basal and stress-evoked extracellular DA
concentrations in the mPFC were reduced following ~65%
loss of TH-IR axons in the mPFC. Thus, relatively mod-
erate loss of PFC DA terminals may be sufficient to alter
local extracellular DA concentrations and, in turn, be-
haviors modulated by this system.
Mesoprefrontal DA neurons appear to play a role in several
aspects of cognitive function including working memory and
attention (Chudasama and Robbins 2004; Granon et al. 2000).
Additional studies are required to identify the specific
cognitive dysfunction associated with deficits in T-maze
delayed-response behavior observed in the present study.
Lesion-induced motor and/or motivation deficits may also
contribute to poor performance in a T-maze task. However, the
observation that lesions failed to affect response latencies
(interval between start-box door opening and an arm choice)
and reward retrieval during information runs provides initial
evidence to the contrary. Lesioned rats exhibiting impaired T-
maze performance also sustained ~10%, albeit nonsignificant,
loss of mPFC NE. As suggested by other investigators, the
role of NE (Arnsten 1997) and DA–NE interactions (see
below for further discussion) in these behavioral deficits must
also be considered.
In the present study, rats sustaining ~85% loss of mPFC










































Fig. 4 Effects of chronic DMI (3 mg/day delivered via osmotic
pumps) on performance of control rats and rats previously sustaining
~75% loss of DA in the mPFC in a T-maze delayed-response task
(n=13 DMI-control, n=11 DMI-lesion, n=24 drug-naïve control, n=9
drug-naïve lesion). Delayed-response performance of DMI-treated
control rats was impaired relative to drug-naïve control rats and
DMI-treated lesioned rats. Relative to their respective within-group
alternation trials, naïve-control rats and DMI-lesioned rats ex-
hibited impaired performance only under the 90-s delay condition.
In DMI-control rats, delay trial accuracy did not differ from that
observed during alternation trials and remained significantly below
that of naïve-control and DMI-lesioned rats. Data are presented as
group mean±SEM. +Significantly different from corresponding
within-group alternation trials (paired samples t tests with layered
Bonferroni correction, P≤0.017–0.05)
409
during all phases of T-maze testing. This finding is
consistent with the observation that ~80% loss of mPFC
DA is associated with near-normal basal and stress-evoked
extracellular DA in this brain region (Venator et al. 1999;
Sleipness et al. 2001). Normalization of local extracellu-
lar DA in rats sustaining ~80% loss of mPFC DA may
be due, in part, to partial loss of NE nerve terminals and
the associated NE transporters, thereby reducing uptake
of extracellular DA into NE neurons (Venator et al.
1999). Despite pretreatment with a NE uptake inhibitor,
local infusions of 6-OHDA frequently induce a decrease in
mPFC NE content. Although the present data are not con-
sistent with previous reports that PFC DA depletions in this
range impair delayed response in nonhuman primates
(Brozoski et al. 1979; Roberts et al. 1994), subjects in the
latter studies also sustained larger NE depletions than our
animals. Differences in the relative loss of NE and DA may
be critical in determining the effects of 6-OHDA lesions of
the PFC on delayed-response behavior. In fact, lesions of
the cortical NE innervation have been shown to alter other
behavioral effects of PFC DA depletions (Ravard et al.
1990; Taghzouti et al. 1988). As with lesion studies, results
of studies using acute pharmacological manipulations gen-
erally support a role for mPFC DA neurons in working
memory that is much more complex than the originally
hypothesized direct relationship between PFC D1 receptor
activation and working memory (Arnsten 1997; Romanides
et al. 1999; Sawaguchi and Goldman-Rakic 1991;
Sawaguchi and Goldman-Rakic 1994; Seamans et al.
1998; Williams and Goldman-Rakic 1995; Zahrt et al.
1997). Investigators have begun to consider the importance
of basal DA tone and interactions between PFC DA and
other neurotransmitter systems, such as NE-containing
neurons, in the modulation of cognitive function (Granon
et al. 2000; Romanides et al. 1999; Verma and Moghaddam
1996). In agreement with the latter trend, results of the
present study suggest that DA–NE interactions in the
mPFC play an important role in regulating working mem-
ory function.
Effects of DMI on T-maze performance of control rats
and rats previously sustaining 6-OHDA lesions
of the mPFC
The present study examined the effects of the NE up-
take inhibitor DMI (3 mg/kg/day delivered via osmotic
pumps) on T-maze delayed-response behavior in control
rats and rats previously sustaining 6-OHDA lesions of the
mPFC. Chronic DMI impaired the performance of control
rats on alternation and delay trials. In this case, perfor-
mance deficits were due to rats failing to make an arm
selection on the choice runs of alternation and delay trials.
DMI-treated control rats appeared to be motivated to per-
form the task in that they did retrieve the reinforcer during
information runs. Thus, it is unlikely that the disruption in
performance is due to entirely to a sedative effect of the
drug. We are aware of only one study examining the effects
of a NE uptake inhibitor on normal cognition. In that study,
acute administration of a NE uptake inhibitor enhanced
working memory in normal humans (Rammsayer et al.
2001). In contrast, results of studies using direct-acting
agonists and antagonists suggest that NE acts at α1- and
α2-receptors in the PFC to impair and facilitate, respec-
tively, working memory in intact rodents and primates
(Arnsten et al. 1999; Avery et al. 2000; Birnbaum et al.
1999; Coull et al. 1995; Franowicz and Arnsten 1998;
Franowicz et al. 1999; Li and Mei 1994; Mao et al. 1999;
Sawaguchi 1998). It is possible that the cognitive deficits
observed in the present study are due to DMI-induced
increases in mPFC NE, biasing the system in favor of α1-
over α2-receptor-mediated events. However, DMI also
increases extracellular DA in the mPFC of naïve rats
(Carboni et al. 1990; Gresch et al. 1995; Yamamoto and
Novotney 1998). It has been suggested that the relationship
between mPFC DA and cognitive function assumes an
inverted U-shaped function such that DA receptor stimu-
lation above or below an optimum level gives rise to
cognitive deficits (Arnsten 1997; Granon et al. 2000; Zahrt
et al. 1997). Thus, DMI-induced increases in extracellular
DA may also have contributed to cognitive impairments in
our drug-treated control rats.
Whereas chronic DMI impaired the behavior of control
rats, drug treatment attenuated cognitive deficits produced
by partial depletion of mPFC DA and NE (~75 and 35%,
respectively). Differential effects of DMI on cognitive
performance of control and lesioned rats do not appear to
be related to a confounding influence of the drug on motor
behavior since DMI increased choice latencies (interval
between start-box door opening and an arm choice) in both
groups. Both direct and indirect NE agonists have been
reported to alleviate cognitive dysfunction thought to be
due to reduced cortical noradrenergic transmission. For
example, NE uptake inhibitors attenuate cognitive deficits
in individuals suffering from depression and attention
deficit hyperactivity disorder (Ferguson et al. 2003; Popper
2000). In experimental animals, deficits in cognitive func-
tion associated with aging, chronic reserpine, or 6-OHDA
lesions of the PFC are reduced by α2-receptor agonists
administered systemically or directly into the PFC (Arnsten
et al. 1988; Arnsten and Goldman-Rakic 1985; Cai et al.
1993; Carlson et al. 1992; Franowicz et al. 1999). Results
of the present study suggest that NE uptake inhibitors are
effective in reducing cognitive deficits associated with a
more selective loss of DA in the mPFC, as may be the case
in schizophrenia. DMI-induced attenuation of the lesion-
induced deficits in T-maze behavior may be related to drug-
induced increases in DA and/or NE. In fact, systemic DMI
has been found to increase extracellular DA and NE in
the mPFC of rats previously sustaining similar lesions to
those described in the present study (Sleipness et al. 2001).
Although DA agonists attenuate cognitive deficits in
schizophrenic subjects (Daniel et al. 1991), the risk of
drug-induced psychoses prohibits their use in the clinical
population. The psychotomimetic effects of the direct and
indirect acting DA agonists may be due to drug-induced
alterations in activity of subcortical DA systems. Because
DMI increases extracellular DA and NE concentrations in
410
the mPFC while leaving subcortical DA largely unaffected,
this and other NE uptake inhibitors may be useful adjuncts
in the treatment of cognitive abnormalities associated with
schizophrenia.
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